Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Sweden beats France, Britain relegated after losing to Norway at hockey worlds
PRAGUE (AP) — Sweden beat France 3-1 to preserve a perfect record at the ice hockey world championsh2024-05-21China to Launch TCM Pilot Projects on Myopia Prevention
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Children Find Snow Sports Cool, Survey Reveals
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Various Events Held Across China to Celebrate Upcoming Lantern Festival
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21- Israel’s defense minister said Monday the military would expand its operations in the southern Gaza2024-05-21
China Steps up Personality Rights Protection on Internet
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment